uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Angiogenesis and mast cells in Hodgkin lymphoma
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Genetics and Pathology.
Show others and affiliations
Responsible organisation
2005 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 19, no 12, 2360-2362 p.Article in journal, Letter (Refereed) Published
Place, publisher, year, edition, pages
2005. Vol. 19, no 12, 2360-2362 p.
Keyword [en]
angiogenesis, mast cell, Hodgkin lymphoma, prognosis
National Category
Clinical Medicine
Research subject
Oncology
Identifiers
URN: urn:nbn:se:uu:diva-80595DOI: 10.1038/sj.leu.2403992PubMedID: 16224482OAI: oai:DiVA.org:uu-80595DiVA: diva2:108509
Available from: 2006-10-02 Created: 2009-04-02 Last updated: 2017-12-14Bibliographically approved
In thesis
1. Hodgkin Lymphoma – an Interplay Between Tumour Cell and Microenvironment
Open this publication in new window or tab >>Hodgkin Lymphoma – an Interplay Between Tumour Cell and Microenvironment
2009 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Hodgkin lymphoma (HL) is a malignant disorder characterised by few tumour cells surrounded by a massive infiltrate of inflammatory cells, fibrosis, and microvessels. Therefore, it is a good model in which to study the interplay between tumour cells and the microenvironment.

In a population-based series, stage IIB had poor prognosis, equivalent to the most advanced stage (stage IV). The most prominent negative prognostic factor was tumour bulk in the mediastinum (often large fibrotic tumours).

The tumour cells expressed interleukin-9 (IL-9) in their cytoplasm in half of the cases. These cases had an over representation of nodular sclerosis histology (characterised by fibrotic bands) and infiltration of eosinophils and mast cells in the tumours. Despite this, IL-9 expression was not a negative prognostic factor.

A role of inflammatory cells is to contribute to angiogenesis. Yet, a correlation between high microvessel count and high mast cell number in HL tumours was not identified, in contrast to other lymphomas. However, a correlation to poor prognosis was seen for cases with high microvessel count.

Eosinophils contain eosinophil cationic protein (ECP). ECP was cytotoxic to cells from two HL cell lines of B-cell origin and one HL line of T-cell origin. At high concentrations, the cytotoxic effect was not as pronounced for the line of T-cell origin. If the in vitro cell lines are representative of HL in vivo, eosinophils may have different roles in different HL tumours.

In addition to the effect from tumour cells, host-related factors contribute to the inflammatory infiltrate in HL. A history of asthma and hives, and carrying the ECP434GG genotype were associated with elevated numbers of eosinophils, whereas, history of tobacco smoking was associated with lower numbers.

HL is a complex tumour consisting of recruited and subverted normal cells, fibrosis and angiogenesis: these constitute the microenvironment, which likely supports tumour cell growth, and differs between patients.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2009. 66 p.
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 449
National Category
Medical and Health Sciences
Research subject
Oncology
Identifiers
urn:nbn:se:uu:diva-100593 (URN)978-91-554-7494-2 (ISBN)
Public defence
2009-05-16, Auditorium Minus Gustavianum, Akademigatan 3, Uppsala, 09:15 (English)
Opponent
Supervisors
Available from: 2009-04-24 Created: 2009-04-02 Last updated: 2009-04-27Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.nature.com/leu/journal/v19/n12/pdf/2403992a.pdf

Authority records BETA

Glimelius, IngridSundström, ChristerMolin, DanielAmini, Rose-MarieEnblad, Gunilla

Search in DiVA

By author/editor
Glimelius, IngridSundström, ChristerMolin, DanielAmini, Rose-MarieEnblad, Gunilla
By organisation
OncologyDepartment of Oncology, Radiology and Clinical ImmunologyDepartment of Genetics and Pathology
In the same journal
Leukemia
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 851 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf